Praxis Precision Medicines, Inc. Common Stock (PRAX)
Praxis Precision Medicines, Inc. (PRAX) is a biotechnology company focused on developing targeted therapies for neuroscience and rare diseases. The company leverages precision medicine approaches to create treatments tailored to specific genetic and molecular profiles, aiming to improve outcomes for patients with neurological and neuropsychiatric conditions.
Company News
Praxis Precision Medicines plans to raise approximately $525 million through a public offering of 3,025,480 common stock shares and pre-funded warrants at $157.00 per share, with underwriters including TD Cowen, Piper Sandler, Guggenheim Securities, and Truist Securities.
Praxis Precision Medicines reported a wider Q2 2025 loss of ($3.31) per share, with no revenue and doubled research expenses. The company continues advancing clinical trials for neurological disorder treatments, with promising results in epilepsy drug vormatrigine and receiving Breakthrough Therapy Designation for relutrigine.
Needham initiated coverage on Praxis Precision Medicines Inc (NASDAQ:PRAX), a clinical-stage biopharmaceutical company, engaged in the development of therapies for central nervous system disorders. The company’s lead product ulixacaltamide for essential tremor (ET) is undergoing Essential3 Phase 3 program, with topline results expected in the s...
JAZZ shares are down 5% as it fails to achieve statistical significance on the primary and key secondary endpoint in a mid-stage tremor study on suvecaltamide.
What the latest PPI inflation data signals for inflation & the stock market today. The post PPI Report Live: Producer Price Inflation Report Is Out, Here’s What It Shows appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.